Literature DB >> 19273697

Simplifying the TNM system for clinical use in differentiated thyroid cancer.

Adedayo A Onitilo1, Jessica M Engel, Catharina Ihre Lundgren, Per Hall, Lukman Thalib, Suhail A R Doi.   

Abstract

PURPOSE: The TNM stratification has been found useful at stratifying patients with differentiated thyroid carcinoma (DTC) into prognostic risk groups. However, it is cumbersome to implement clinically given the large number of bins within this system and the complicated system of arriving at stage information. PATIENTS AND METHODS: We decided to quantify each variable in this system to arrive at a simplified quantitative alternative to the TNM system (QTNM) and compare this with the conventional system. We used our electronic record system to identify 614 cases of DTC managed at our institution from 1987 to 2006. Cancer-specific survival (CSS) and disease-free survival (DFS) were calculated by the Kaplan-Meier method, and a simplified QTNM score was devised using a Cox proportional hazards model.
RESULTS: We were able to quantify the TNM system as follows: 4 points each for age older than 45 years and presence of neck nodal metastases while 6 points for tumor size larger than 4 cm or extrathyroidal extension and 1 point for nonpapillary DTC. A sum of 0 to 5 points was low risk, 6 to 10 points intermediate, and 11 to 15 points high risk. Comparison with the conventional TNM system and two other systems revealed similar or better discrimination with the QTNM and this discrimination was maintained when this risk stratification was applied to a unique validation set.
CONCLUSION: The QTNM system as opposed to the conventional TNM system seems to be a simple and effective method for risk stratification for both recurrence and cancer-specific mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19273697     DOI: 10.1200/JCO.2008.20.2382

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Cancer: QTNM: a simplified TNM or just another staging system?

Authors:  Brian H H Lang; Chung-Yau Lo
Journal:  Nat Rev Endocrinol       Date:  2009-10       Impact factor: 43.330

2.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.

Authors:  Daniel Mankarios; Peter Baade; Pip Youl; Robin H Mortimer; Adedayo A Onitilo; Anthony Russell; Suhail A R Doi
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

3.  Is there a need for yet another staging system for differentiated thyroid cancer?

Authors:  Michael Bouvet
Journal:  Endocrine       Date:  2014-02-16       Impact factor: 3.633

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry.

Authors:  Hop S Tran Cao; Lily E Johnston; David C Chang; Michael Bouvet
Journal:  Surgery       Date:  2012-04-11       Impact factor: 3.982

Review 6.  Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.

Authors:  Einat Slonimsky; Mark Tulchinsky
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

7.  Is a simplified TNM staging system more clinically relevant than the American Joint Committee on Cancer system for the follicular variant of papillary thyroid cancer?

Authors:  Di Hu; Yueye Huang; Wen Zeng; Sichao Chen; Yihui Huang; Man Li; Wei Long; Jianglong Huang; Wei Wei; Chao Zhang; Zeming Liu; Liang Guo
Journal:  Ann Transl Med       Date:  2020-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.